Acta Neuropathologica

, Volume 114, Issue 3, pp 299–303

More frequent Lewy bodies but less frequent Alzheimer-type lesions in multiple system atrophy as compared to age-matched control brains

Correspondence

References

  1. 1.
    Armstrong RA, Lantos PL, Cairns NJ (2007) Spatial topography of the neurofibrillary tangles in cortical and subcortical regions in progressive supranuclear palsy. Parkinsonism Relat Disord 13:50–54PubMedCrossRefGoogle Scholar
  2. 2.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239–259CrossRefGoogle Scholar
  3. 3.
    Brown R (2007) Cognitive dysfunction in MSA (abstr.). In: Internatl. congr. on multiple system atrophy. Innsbruck, Austria, 12–13 January 2007Google Scholar
  4. 4.
    Burk K, Daum I, Rub U (2006) Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord 21:772–776PubMedCrossRefGoogle Scholar
  5. 5.
    Giasson BI, Mabon ME, Duda JE, Montine TJ, Robertson D, Hurtig HI, Lee VM, Trojanowski JQ (2003) Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy. Acta Neuropathol (Berl) 106:243–250CrossRefGoogle Scholar
  6. 6.
    Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163:94–98PubMedCrossRefGoogle Scholar
  7. 7.
    Jellinger KA (1998) Alzheimer-type lesions in Huntington’s disease. J Neural Transm 105:787–799PubMedCrossRefGoogle Scholar
  8. 8.
    Jellinger KA (2004) Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 111:1219–1235PubMedCrossRefGoogle Scholar
  9. 9.
    Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329–339PubMedCrossRefGoogle Scholar
  10. 10.
    Jellinger KA, Seppi K, Wenning GK (2005) Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 20(Suppl 12):S29–S36PubMedCrossRefGoogle Scholar
  11. 11.
    Josephs KA, Tsuboi Y, Cookson N, Watt H, Dickson DW (2004) Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Arch Neurol 61:1579–1584PubMedCrossRefGoogle Scholar
  12. 12.
    Kawamoto Y, Akiguchi I, Nakamura S, Honjyo Y, Shibasaki H, Budka H (2002) 14-3-3 Proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J Neuropathol Exp Neurol 61:245–253PubMedGoogle Scholar
  13. 13.
    Lantos PL, Quinn N (2003) Dementia with Lewy bodies. In: Dickson DW (ed) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, pp 188–199Google Scholar
  14. 14.
    Lindboe CF, Hansen HB (1998) The frequency of Lewy bodies in a consecutive autopsy series. Clin Neuropathol 17:204–209PubMedGoogle Scholar
  15. 15.
    Mikolaenko I, Pletnikova O, Kawas CH, O’Brien R, Resnick SM, Crain B, Troncoso JC (2005) Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore longitudinal study of aging (BLSA). J Neuropathol Exp Neurol 64:156–162PubMedGoogle Scholar
  16. 16.
    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41:479–486PubMedGoogle Scholar
  17. 17.
    Mochizuki A, Komatsuzaki Y, Shoji S (2002) Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson’s disease. Acta Neuropathol (Berl) 104:534–537Google Scholar
  18. 18.
    Ozawa T, Paviour D, Quinn NP, Josephs KA, Sangha H, Kilford L, Healy DG, Wood NW, Lees AJ, Holton JL, Revesz T (2004) The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127:2657–2671PubMedCrossRefGoogle Scholar
  19. 19.
    Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I (2005) Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol 57:82–91PubMedCrossRefGoogle Scholar
  20. 20.
    Sikorska B, Papierz W, Preusser M, Liberski PP, Budka H (2007) Synucleinopathy with features of both multiple system atrophy and dementia with Lewy bodies. Neuropathol Appl Neurobiol 33:126–129PubMedGoogle Scholar
  21. 21.
    Terni B, Rey MJ, Boluda S, Escribano BT, Sabate MP, Calopa M, van Leeuwen FW, Ferrer I (2007) Mutant ubiquitin and p62 immunoreactivity in cases of combined multiple system atrophy and Alzheimer’s disease. Acta Neuropathol (Berl) 113:403–416CrossRefGoogle Scholar
  22. 22.
    Uchikado H, DelleDonne A, Ahmed Z, Dickson DW (2006) Lewy bodies in progressive supranuclear palsy represent an independent disease process. J Neuropathol Exp Neurol 65:387–395PubMedGoogle Scholar
  23. 23.
    Uchikado H, Delledonne A, Uitti R, Dickson DW (2006) Coexistence of PSP and MSA: a case report and review of the literature. Acta Neuropathol (Berl) 111:186–192CrossRefGoogle Scholar
  24. 24.
    Wenning GK, Jellinger KA (2005) The role of alpha-synuclein and tau in neurodegenerative movement disorders. Curr Opin Neurol 18:357–362PubMedCrossRefGoogle Scholar
  25. 25.
    Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP (1995) Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 58:160–166PubMedCrossRefGoogle Scholar
  26. 26.
    Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP (1997) Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 12:133–147PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Institute of Clinical NeurobiologyViennaAustria

Personalised recommendations